Kite's CAR-T therapy shows remarkable efficacy and is positioned to reach the market first.
Kite released positive top-line results from its pivotal Zuma-1 trial in conjunction with fourth-quarter results, affirming our confidence in the company’s lead product axi-cel (axicabtagene ciloleucel, or KTE-C19). We plan to increase our $70 per share fair value estimate to account for an increased probability of approval for axi-cel. We anticipate that the gain in our fair value estimate will be partially offset by higher-than-expected operating costs in 2017 as the firm expands investment in...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.